Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitomycin C: a prototype bioreductive agent

A C Sartorelli1, W F Hodnick, M F Belcourt

  • 1Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA.

Oncology Research
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SU-E-J-41: Fluoroscopy Based Adaptive Setup Approach for Thoracic Cancer IGRT.

Medical physics·2017
Same author

SU-E-T-10: Monte Carlo Study of the Dose Enhancement Factor (DEF) for Gold Nano-Particle (GNP) on the Cellular Level.

Medical physics·2017
Same author

A simple and inexpensive method to control oxygen concentrations within physiological and neoplastic ranges.

Analytical biochemistry·2015
Same author

Parameterization of brachytherapy source phase space file for Monte Carlo-based clinical brachytherapy dose calculation.

Physics in medicine and biology·2013
Same author

Local control, toxicity, and cosmesis in women younger than 50 enrolled onto the American Society of Breast Surgeons MammoSite Radiation Therapy System registry trial.

Annals of surgical oncology·2009
Same author

1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition.

Cancer chemotherapy and pharmacology·2004

Hypoxia in solid tumors causes resistance to cancer treatments. Mitomycin C (MC) is preferentially activated in low-oxygen tumor cells, enhancing therapeutic effects when combined with radiation therapy.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Chemistry

Background:

  • Hypoxic cells in solid tumors are resistant to radiation and chemotherapy.
  • Tumor hypoxia creates an environment exploitable through reductive processes.

Purpose of the Study:

  • To investigate the therapeutic potential of Mitomycin C (MC) in combination with x-irradiation for solid tumors.
  • To evaluate the preferential activation and toxicity of MC in hypoxic tumor cells.

Main Methods:

  • Reductive activation of Mitomycin C (MC) by oxidoreductases.
  • Assessment of DNA adduct formation as a marker of MC activity.
  • Combination therapy studies using MC and x-irradiation in animal models and clinical trials.

Main Results:

Related Experiment Videos

  • Mitomycin C (MC) is preferentially activated under hypoxic conditions, leading to greater toxicity in oxygen-deficient cells.
  • MC forms mono- and bis-adducts with DNA, indicating DNA as a primary target.
  • Combined MC and x-irradiation demonstrated enhanced cytodestructive effects on solid tumors in animal studies.

Conclusions:

  • Targeting the hypoxic fraction of solid tumors with combined Mitomycin C (MC) and x-irradiation enhances therapeutic efficacy.
  • This combined approach shows promise for improving the curability of localized neoplasms, particularly in head and neck cancers.